What is Stereotaxis's market cap?

Stereotaxis (STXS) has a market capitalization of $170.1M and trades on AMEX.

What is Stereotaxis's revenue and profitability?

Stereotaxis generated $31.2M in trailing twelve-month revenue with a net loss of $21.7M, representing a net margin of -69.5%. Gross margin stands at 53.9%, with free cash flow of -$16.1M. These figures are based on the Q1 2026 filing.

Who are Stereotaxis's competitors?

Stereotaxis's key competitors include Medtronic, Boston Scientific, Abbott Laboratories, and others. These companies compete in similar markets and product categories.

Who does Stereotaxis partner with?

Stereotaxis's notable partners include Biosense Webster, Johnson & Johnson.

What subsidiaries does Stereotaxis have?

Stereotaxis's subsidiaries include Access Point Technologies EP, Inc..

Where is Stereotaxis headquartered?

Stereotaxis is headquartered in United States of America and employs approximately 122 people. It has been publicly traded since 2004.

Stereotaxis

STXS

Stereotaxis designs, manufactures, and markets robotic systems, instruments, and information systems for interventional laboratories.

Market cap

$170.06M-11.7%

Revenue$31.2M+13.4%

Net income-$21.7M+14.5%

Free cash flow-$16.1M-69.4%

EPS (diluted)-$0.24+22.6%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 12, 2026

Revenue$6.3MMiss by $2.2M EPS-$0.03Beat by $0.01

Read the full report

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$8.4M

EPS estimate-$0.03

Financials

Q1 2026

Income statement

See full

Revenue$6.3M-15.8%

Gross profit$3.8M-6.6%

Operating income-$6.0M-0.9%

Net income-$5.9M-0.7%

EPS (diluted)-$0.06+14.3%

Balance sheet

See full

Cash & equivalents$14.6M+36.7%

Total debt$5.3M-10.0%

Total equity$14.4M+399%

Total assets$54.0M+18.2%

Cash flow

See full

Operating cash flow-$3.4M-93.5%

CapEx$79.0K—

Free cash flow-$3.5M—

Valuation & ratios

Valuation

See full

Market cap$170.06M-11.7%

Enterprise value$160.73M-12.1%

P/S5.5×-0.3×

Profitability

See full

Gross margin53.9%+0.5pp

Operating margin-71%-14.0pp

Net margin-69.5%-13.7pp

Returns & leverage

See full

Return on equity-251.5%-29.9pp

Debt / equity0.4×-1.7×

Current ratio1.6×+0.5×

Competitors

By market cap

Abbott$164.43B-29.3%

Stryker$125.40B-16.4%

Medtronic$105.46B-6.1%

Boston Scientific$66.9B-56.5%

Merit Medical Systems$4.3B-20.8%

ITG

Integer Holdings$3.1B-23.5%

Stereotaxis$170.1M-7.6%

Microbot Medical$124.9M+31.5%

By revenue growth

Microbot Medical+62.4%

Boston Scientific+17.4%

Stereotaxis+13.4%

Merit Medical Systems+11.1%

Integer Holdings+6.3%

By net margin

Boston Scientific17.26%+5.7pp

Abbott13.91%-18.0pp

Stryker13.21%+0.9pp

Medtronic13.2%-0.7pp

Merit Medical Systems9.03%+0.2pp

ITG

Integer Holdings7.64%+3.2pp

Stereotaxis-69.5%+22.7pp

Microbot Medical-3,669.88%+2,493pp

Profile

Stereotaxis designs, manufactures, and markets robotic systems, instruments, and information systems for interventional laboratories. The company's core value proposition is its Robotic Magnetic Navigation (RMN) technology, which uses computer-controlled magnetic fields to precisely steer flexible catheters and devices during endovascular procedures. This technology is designed to improve procedural precision, safety, and efficiency while reducing radiation exposure for both patients and physicians.

Competitive position

Stereotaxis is a pioneer in robotic magnetic navigation for electrophysiology, holding an extensive patent portfolio and a unique position as a provider of remote digital catheter tip control.

GeographiesUnited States, Europe, China, Canada, Japan

Customer segmentsHospitals, Specialized Medical Centers

Business modelCapital Equipment Sales, Razor-and-blade, Service and Maintenance, SaaS

SuppliersFluoroscopy system manufacturers, Contract manufacturers, Specialized magnet component suppliers, Software module licensors

CustomersHospitals, Interventional cardiologists, Electrophysiologists, Medical distributors

CountryUnited States of America

Listed2004

Employees122.0

CEODavid L. Fischel

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websitestereotaxis.com

FilingsSEC EDGAR

Ask your AI about Stereotaxis.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Stereotaxis's market cap?: Stereotaxis (STXS) has a market capitalization of $170.1M and trades on AMEX.
What is Stereotaxis's revenue and profitability?: Stereotaxis generated $31.2M in trailing twelve-month revenue with a net loss of $21.7M, representing a net margin of -69.5%. Gross margin stands at 53.9%, with free cash flow of -$16.1M. These figures are based on the Q1 2026 filing.
Who are Stereotaxis's competitors?: Stereotaxis's key competitors include Medtronic, Boston Scientific, Abbott Laboratories, and others. These companies compete in similar markets and product categories.
Who does Stereotaxis partner with?: Stereotaxis's notable partners include Biosense Webster, Johnson & Johnson.
What subsidiaries does Stereotaxis have?: Stereotaxis's subsidiaries include Access Point Technologies EP, Inc..
Where is Stereotaxis headquartered?: Stereotaxis is headquartered in United States of America and employs approximately 122 people. It has been publicly traded since 2004.